Year: 2023

Updated data from BEACON continued to demonstrate significant, consistent reductions in protoporphyrin IX (PPIX) > 40% and improvements in sunlight toleranceRobust and consistent improvements across all measures of sunlight tolerance, including >3x improvement over historical control of precedented pivotal endpointBitopertin was generally well-tolerated with stable hemoglobin at both dose levelsEarlier today, Disc also announced initial positive data from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia, demonstrating improvements in hemoglobin and reductions in transfusion burdenWATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients...

MINNEAPOLIS, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) (“Sun Country Airlines”) today announced the pricing of the previously announced secondary public offering of 4,000,000 shares of its common stock by an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc. (the “Selling Stockholder”). The offering is expected to close, subject to customary closing conditions, on December 14, 2023. The underwriters will have a 30-day option to purchase up to an additional 600,000 shares of common stock from the Selling Stockholder. Sun Country Airlines is not selling any shares and will not receive any proceeds from the offering. In addition, Sun Country Airlines has agreed to purchase from the underwriters approximately $5 million of shares of common stock that...

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy • At the 12 mg dose, cohorts demonstrated favorable activity and safety profile:– 63% ORR; with 53% VGPR or better –– CRS reported in 16% of patients, no Grade 3 events, no ICANS – • Findings support further clinical development at the 12 mg RP2D SOUTH SAN FRANCISCO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition...

VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its December 2023 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at December 21, 2023. The December 2023 distribution will be paid on December 29, 2023. The Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual property used by Keg Restaurants Ltd. (“KRL”). In exchange for use of those trademarks, KRL pays the Fund a royalty of 4% of gross sales of Keg restaurants included in the royalty pool. With approximately 10,000 employees, over 100 restaurants and annual system sales...

New York, NY, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, SAGAR”) (the “Company”) received a delisting notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on December 5, 2023. The Company intends to file an appeal, and take all possible steps to maintain its Nasdaq listing. Following is the core text of the letter received from Nasdaq on December 5, 2023: On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023...

Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting autologous CAR-T therapy being evaluated for hematologic malignancies and autoimmune disease SAN DIEGO and SUZHOU, China and SHANGHAI, China, Dec. 11, 2023 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented updated results from the clinical investigator-initiated trial (IIT) of GC012F for treatment of newly diagnosed multiple...

SAN DIEGO and TORONTO, Dec. 11, 2023 (GLOBE NEWSWIRE) — StateHouse Holdings Inc. (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, today announced that it has issued a total of 734,000 restricted share units (“RSUs”) to certain directors, officers, and employees of the Company as of December 5, 2023. About StateHouse Holdings Inc. StateHouse, a vertically integrated enterprise with cannabis licenses covering retail, major brands, distribution, cultivation, nursery, and manufacturing, is one of the oldest and most respected cannabis companies in California. Founded in 2006, its predecessor company Harborside was awarded one of the first six medical cannabis licenses granted in the United States. Today, the Company operates 13 dispensaries covering...

TACOMA, Wash, Dec. 11, 2023 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (Nasdaq: HCDI, HCDIP, HCDIW, HCDIZ) (collectively with certain of its wholly owned subsidiaries described below, “HCDI” or “the Company”), a real estate company involved in all aspects of the land development cycle, and certain of its wholly owned subsidiaries today announced that the Company has voluntarily filed for protection under Chapter 11 of the United States Bankruptcy Code in the Western District of Washington at Tacoma (collectively, the “Chapter 11 cases”) to pursue an orderly wind down or restructuring of its business. The Company has filed a number of customary first day motions with the Bankruptcy Court that will allow it to continue operating in the ordinary course of business while it prepares a Plan of Reorganization to ensure that it...

CALGARY, Alberta, Dec. 11, 2023 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (“Canoe” or the “Fund”)(TSX – EIT.UN) today announced that units accepted for the 2023 voluntary cash redemption will be redeemed at a price of $12.41 per unit (rounded) in Canadian dollars. This price is equal to 95% of the average net asset value per unit based on the three business days preceding the redemption date of December 8, 2023, less direct costs. Payment of the redemption proceeds will be made on or before January 3, 2024. About Canoe EIT Income FundCanoe EIT Income Fund is one of Canada’s largest closed-end investment funds, designed to maximize monthly distributions and capital appreciation by investing in a broadly diversified portfolio of high quality securities. The Fund is listed on the TSX under the symbol EIT.UN, and is actively managed...